Mylan Makes Its Move, Buys Abbott Generics In Tax Inversion Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
You may also be interested in...
Emerging Markets Earnings: Abbott Laboratories Casts Fortune Abroad
Emerging markets now account for nearly half of Abbott Laboratories sales – a figure set to grow through regional focus and acquisitions, leading Chicago-based CEO Miles White and other executives to skip over vast portions of the globe in the third quarter earnings call.
Emerging Markets Earnings: Abbott Laboratories Casts Fortune Abroad
Emerging markets now account for nearly half of Abbott Laboratories sales – a figure set to grow through regional focus and acquisitions, leading Chicago-based CEO Miles White and other executives to skip over vast portions of the globe in the third quarter earnings call.
Mylan Increases Injectable Presence, But In Declining Market
The generics company added to its arsenal of injectable drugs by acquiring rights to Aspen’s DVT treatment Arixtra, but the anticoagulant faces tough competition from oral entrants.